Suppr超能文献

确定可减少体外脐血祖细胞扩增但不改变体内人类再增殖细胞功能的生长因子条件。

Identification of growth factor conditions that reduce ex vivo cord blood progenitor expansion but do not alter human repopulating cell function in vivo.

作者信息

Levac Krysta, Karanu Francis, Bhatia Mickie

机构信息

Robarts Research Institute, Stem Cell Biology and Regenerative Medicine, London, Ontario, Canada.

出版信息

Haematologica. 2005 Feb;90(2):166-72.

Abstract

BACKGROUND AND OBJECTIVES

Ex vivo expansion of primitive hematopoietic cells for transplantation is an important step to realizing the optimal clinical potential of human cord blood (CB). We aimed to characterize minimal growth factor (GF) conditions that allow ex vivo expansion of primitive cells, including candidate hematopoietic stem cells.

DESIGN AND METHODS

Here, we directly investigated the effect of thrombopoietin (TPO) on progenitors and repopulating cells using serum-free culture of CB Lin-CD34+CD38- cells in two different minimal GF conditions: stem cell factor (SCF)+FLT-3-L (termed S/F) and SCF+FLT-3-L+TPO (termed S/F/T).

RESULTS

While S/F media supported only low levels of total cell and CFU (colony-forming unit) expansion, the addition of TPO (S/F/T) partially restored cell proliferation, and completely restored CFU expansion to levels observed using full GF conditions (SCF+FLT-3-L+interleukin (IL)-3 (IL-3)+ IL-6+ granulocyte colony-stimulating factor (G-CSF). Intravenous transplantation of either S/F- or S/F/T-expanded cells into NOD/SCID mice resulted in similar frequencies and levels of multilineage reconstitution.

INTERPRETATION AND CONCLUSIONS

The use of minimal cytokine stimulation and simultaneous assessment of CFU and SRC indicate that hematopoietic progenitors and in vivo-detected repopulating cells are differentially responsive to TPO; CFU expand in response to TPO but SRC do not. In addition, our study suggests that TPO can functionally replace IL-3+IL-6+G-CSF for CFU expansion of ex vivo cultured CB Lin-CD34+CD38- hematopoietic stem cells.

摘要

背景与目的

体外扩增原始造血细胞用于移植是实现人类脐血(CB)最佳临床潜力的重要一步。我们旨在确定能够实现包括候选造血干细胞在内的原始细胞体外扩增的最低生长因子(GF)条件。

设计与方法

在此,我们在两种不同的最低GF条件下,即干细胞因子(SCF)+FLT-3配体(称为S/F)和SCF+FLT-3配体+血小板生成素(TPO)(称为S/F/T),使用无血清培养的CB Lin-CD34+CD38-细胞,直接研究血小板生成素(TPO)对祖细胞和再增殖细胞的影响。

结果

虽然S/F培养基仅支持低水平的总细胞和集落形成单位(CFU)扩增,但添加TPO(S/F/T)可部分恢复细胞增殖,并将CFU扩增完全恢复至使用完全GF条件(SCF+FLT-3配体+白细胞介素(IL)-3(IL-3)+IL-6+粒细胞集落刺激因子(G-CSF))时观察到的水平。将S/F或S/F/T扩增的细胞静脉注射到NOD/SCID小鼠体内,导致多谱系重建的频率和水平相似。

解读与结论

使用最低细胞因子刺激并同时评估CFU和造血干细胞表明,造血祖细胞和体内检测到的再增殖细胞对TPO的反应不同;CFU对TPO有反应而造血干细胞没有。此外,我们的研究表明,TPO在功能上可替代IL-3+IL-6+G-CSF用于体外培养的CB Lin-CD34+CD38-造血干细胞的CFU扩增。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验